Home > Research > Publications & Outputs > Assessment of nonreleasing antifungal surface c...

Links

Text available via DOI:

View graph of relations

Assessment of nonreleasing antifungal surface coatings bearing covalently attached pharmaceuticals

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Assessment of nonreleasing antifungal surface coatings bearing covalently attached pharmaceuticals. / Naderi, J.; Griesser, H.J.; Coad, B.R.
In: Biointerphases, Vol. 16, No. 6, 061001, 30.11.2021, p. 061001.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

APA

Vancouver

Naderi J, Griesser HJ, Coad BR. Assessment of nonreleasing antifungal surface coatings bearing covalently attached pharmaceuticals. Biointerphases. 2021 Nov 30;16(6):061001. 061001. Epub 2021 Nov 18. doi: 10.1116/6.0001099

Author

Bibtex

@article{adfab359f5684d6085d7ef5b1be2e941,
title = "Assessment of nonreleasing antifungal surface coatings bearing covalently attached pharmaceuticals",
abstract = "There are many reports of antimicrobial coatings bearing immobilized active agents on surfaces; however, strong analytical evidence is required to verify that the agents are indeed covalently attached to the surface. In the absence of such evidence, antimicrobial activity could result from a release of active agents. We report a detailed assessment of antifungal surface coatings prepared using covalent attachment chemistries, with the aim of establishing a set of instrumental and biological evidence required to convincingly demonstrate antimicrobial activity due to nonreleasing, surface active compounds and to exclude the alternate possibility of activity due to release. The strongest biological evidence initially supporting permanent antifungal activity was the demonstration of the ability to reuse samples in multiple, sequential pathogen challenges. However, additional supporting evidence from washing studies and instrumental analysis is also required to probe the possibility of gradual desorption of strongly physisorbed compounds versus covalently attached compounds. Potent antifungal surface coatings were prepared from approved pharmaceutical compounds from the echinocandin drug class (caspofungin, anidulafungin, and micafungin) and assessed by microbiological tests and instrumental methods. Carbonyl diimidazole linking chemistry enabled covalent attachment of caspofungin, anidulafungin, and micafungin to plasma polymer surfaces, with antifungal surface activity likely caused by molecular orientations that present the lipophilic tail toward interfacing fungal cells. This study demonstrates the instrumental and biological evidence required to convincingly ascertain activity due to nonreleasing, surface active compounds and summarize these as three criteria for assessing other reports on surface-immobilized antimicrobial compounds. ",
keywords = "Antifungal agents, Carbonyl compounds, Controlled drug delivery, Fungi, Microorganisms, Targeted drug delivery, Active agents, Anidulafungin, Anti-microbial activity, Antifungal activities, Antifungals, Antimicrobial coatings, Caspofungin, Covalent attachment, Surface coatings, Surface-active compounds, Coatings",
author = "J. Naderi and H.J. Griesser and B.R. Coad",
year = "2021",
month = nov,
day = "30",
doi = "10.1116/6.0001099",
language = "English",
volume = "16",
pages = "061001",
journal = "Biointerphases",
issn = "1934-8630",
publisher = "American Institute of Physics Inc.",
number = "6",

}

RIS

TY - JOUR

T1 - Assessment of nonreleasing antifungal surface coatings bearing covalently attached pharmaceuticals

AU - Naderi, J.

AU - Griesser, H.J.

AU - Coad, B.R.

PY - 2021/11/30

Y1 - 2021/11/30

N2 - There are many reports of antimicrobial coatings bearing immobilized active agents on surfaces; however, strong analytical evidence is required to verify that the agents are indeed covalently attached to the surface. In the absence of such evidence, antimicrobial activity could result from a release of active agents. We report a detailed assessment of antifungal surface coatings prepared using covalent attachment chemistries, with the aim of establishing a set of instrumental and biological evidence required to convincingly demonstrate antimicrobial activity due to nonreleasing, surface active compounds and to exclude the alternate possibility of activity due to release. The strongest biological evidence initially supporting permanent antifungal activity was the demonstration of the ability to reuse samples in multiple, sequential pathogen challenges. However, additional supporting evidence from washing studies and instrumental analysis is also required to probe the possibility of gradual desorption of strongly physisorbed compounds versus covalently attached compounds. Potent antifungal surface coatings were prepared from approved pharmaceutical compounds from the echinocandin drug class (caspofungin, anidulafungin, and micafungin) and assessed by microbiological tests and instrumental methods. Carbonyl diimidazole linking chemistry enabled covalent attachment of caspofungin, anidulafungin, and micafungin to plasma polymer surfaces, with antifungal surface activity likely caused by molecular orientations that present the lipophilic tail toward interfacing fungal cells. This study demonstrates the instrumental and biological evidence required to convincingly ascertain activity due to nonreleasing, surface active compounds and summarize these as three criteria for assessing other reports on surface-immobilized antimicrobial compounds.

AB - There are many reports of antimicrobial coatings bearing immobilized active agents on surfaces; however, strong analytical evidence is required to verify that the agents are indeed covalently attached to the surface. In the absence of such evidence, antimicrobial activity could result from a release of active agents. We report a detailed assessment of antifungal surface coatings prepared using covalent attachment chemistries, with the aim of establishing a set of instrumental and biological evidence required to convincingly demonstrate antimicrobial activity due to nonreleasing, surface active compounds and to exclude the alternate possibility of activity due to release. The strongest biological evidence initially supporting permanent antifungal activity was the demonstration of the ability to reuse samples in multiple, sequential pathogen challenges. However, additional supporting evidence from washing studies and instrumental analysis is also required to probe the possibility of gradual desorption of strongly physisorbed compounds versus covalently attached compounds. Potent antifungal surface coatings were prepared from approved pharmaceutical compounds from the echinocandin drug class (caspofungin, anidulafungin, and micafungin) and assessed by microbiological tests and instrumental methods. Carbonyl diimidazole linking chemistry enabled covalent attachment of caspofungin, anidulafungin, and micafungin to plasma polymer surfaces, with antifungal surface activity likely caused by molecular orientations that present the lipophilic tail toward interfacing fungal cells. This study demonstrates the instrumental and biological evidence required to convincingly ascertain activity due to nonreleasing, surface active compounds and summarize these as three criteria for assessing other reports on surface-immobilized antimicrobial compounds.

KW - Antifungal agents

KW - Carbonyl compounds

KW - Controlled drug delivery

KW - Fungi

KW - Microorganisms

KW - Targeted drug delivery

KW - Active agents

KW - Anidulafungin

KW - Anti-microbial activity

KW - Antifungal activities

KW - Antifungals

KW - Antimicrobial coatings

KW - Caspofungin

KW - Covalent attachment

KW - Surface coatings

KW - Surface-active compounds

KW - Coatings

U2 - 10.1116/6.0001099

DO - 10.1116/6.0001099

M3 - Journal article

VL - 16

SP - 061001

JO - Biointerphases

JF - Biointerphases

SN - 1934-8630

IS - 6

M1 - 061001

ER -